Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecasermin in prepubertal children with primary IGF-1 deficiency
2019-001020-36Phase 3
- Sponsor
- Ipsen
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in insulin-like growth factor 1 deficiency comparing Mecasermin parallel-dose arm with Observation control (2 arms). Primary endpoint: First-year height velocity.
02
Drugs
mecasermin
03
Conditions
insulin-like growth factor 1 deficiency
Beyond the preview
Go deeper on 2019-001020-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001020-36.